Experiences in the treatment of advanced hepatocellular carcinoma (HCC) with sorafenib beyond the SHARP trial – Management of side effects

Aims: Sorafenib (Nexavar®, Bayer Health Care, Germany), a novel multikinase inhibitor, was the first agent to demonstrate a statistically significant improvement in overall survival for patients (pts) with advanced HCC (SHARP trial). Therefore, sorafenib will probably be the first-line treatment for advanced HCC during the next years. In clinical practice, prevention and management of side effects such as diarrhea, hand-foot skin reaction and fatigue will be a crucial point to prevent discontinuation of therapy. Patients and Methods: From January to September 2007, 20 pts with advanced HCC were treated in our HC…